The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CELC | +699.92% | +796.34% | +55.06% | +603% |
| S&P | +11.09% | +81.2% | +12.62% | +168% |
Celcuity, Inc. is cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. Its proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
A top biotech fund just made a bold move while Celcuity trades near record highs—here’s what they might see coming next.
One clinical-stage biotech is defying gravity—here’s why its record-breaking run is catching institutional attention.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$41.00K | -20.5% |
| Market Cap | $2.10B | 279.6% |
| Market Cap / Employee | $24.09M | 0.0% |
| Employees | 87 | 58.2% |
| Net Income | -$43,804.00K | -47.0% |
| EBITDA | -$42,808.00K | -42.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $74.25M | 489.1% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $320.25M | 230.1% |
| Short Term Debt | $96.00K | -45.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -43.45% | 1.8% |
| Return On Invested Capital | -45.66% | -2.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$44,873.00K | -117.7% |
| Operating Free Cash Flow | -$44,776.00K | -117.8% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 3.25 | 3.25 | 5.83 | 43.32 | 1286.89% |
| Price to Tangible Book Value | 3.25 | 3.25 | 5.83 | 43.32 | 1286.89% |
| Enterprise Value to EBITDA | -11.65 | -9.09 | -11.69 | -51.77 | 229.92% |
| Return on Equity | -87.5% | -115.4% | -134.5% | -122.0% | 57.53% |
| Total Debt | $97.95M | $98.71M | $99.42M | $320.35M | 229.59% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
